FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The U.S. FDA approved an at-home starting dose for Eisai and Biogen’s Alzheimer’s therapy, letting eligible patients begin treatment with self- or caregiver-administered injections. This regulatory expansion improves convenience and potential uptake versus clinic-only initiation. The approval is a meaningful positive catalyst for the drug’s commercial trajectory.

Analysis

The U.S. FDA approved an at-home starting dose for Eisai and Biogen’s Alzheimer’s therapy, letting eligible patients begin treatment with self- or caregiver-administered injections. This regulatory expansion improves convenience and potential uptake versus clinic-only initiation. The approval is a meaningful positive catalyst for the drug’s commercial trajectory.